SAE Shop Apotheke Europe NV

EQS-News:  Positive judgment of the European Court of Justice strengthens the position of Redcare Pharmacy and its customers.

EQS-News: Redcare Pharmacy N.V. / Key word(s): Statement
 Positive judgment of the European Court of Justice strengthens the position of Redcare Pharmacy and its customers.

27.02.2025 / 12:15 CET/CEST
The issuer is solely responsible for the content of this announcement.


 Positive judgment of the European Court of Justice strengthens the position of Redcare Pharmacy and its customers.

Sevenum, the Netherlands, 27 February 2025 – Redcare Pharmacy welcomes today's judgment of the European Court of Justice that advertising measures that promote the purchase of prescription medicines in the form of direct discounts or payments of an exact amount are allowed.

This confirms Redcare Pharmacy’s long-standing position since the ECJ’s judgment in 2016 (C-148/15, Deutsche Parkinson Vereinigung) that it is entitled to grant bonuses on prescription orders to the benefit of its customers.

“As Europe's leading customer-centric online pharmacy, we welcome this judgment, which offers us the opportunity to further optimise our customer offerings. We will carefully review the judgment,” Olaf Heinrich, CEO of Redcare Pharmacy, comments.

Link to the ECJ press release, English and German version:

 

About Redcare Pharmacy.

Founded in 2001, Redcare Pharmacy (formerly Shop Apotheke Europe) is now the leading online pharmacy in Europe and currently active in seven countries: Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland.

The company is headquartered in Sevenum, NL in the heart of Europe, with further locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven.

As the one-stop pharmacy of the future, Redcare Pharmacy offers around 12.5 million active customers a wide range of more than 150,000 products at fair prices. In addition to over-the-counter medicines, nutritional supplements, beauty and personal care products, and a wide selection of health-related items in all markets, the company also offers prescription drugs to customers in Germany, Switzerland and the Netherlands.

Pharmaceutical safety is always the top priority. With pharmacy at its core, providing sound pharmaceutical advice is clearly at the center of Redcare's focus. The “Care” in the name stands for a wide range of services for all stages of life and health issues: from marketplaces to unique delivery options and medication management.

Redcare Pharmacy N.V. has been listed on the Frankfurt Stock Exchange (Prime Standard) since 2016. As of June 19, 2023, the company is a member of the MDAX selection index.

 

 



27.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


Language: English
Company: Redcare Pharmacy N.V.
Erik de Rodeweg 11-13
5975 WD Sevenum
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail:
Internet: -pharmacy.com
ISIN: NL0012044747, DE000A19Y072
WKN: A2AR94, A19Y072
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2092761

 
End of News EQS News Service

2092761  27.02.2025 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2092761&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
27/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Shop Apotheke Europe NV

 PRESS RELEASE

EQS-News: Aufbauend auf dem Erfolg von 2024, erwartet Redcare Pharmacy...

EQS-News: Redcare Pharmacy N.V. / Schlagwort(e): Jahresergebnis/Prognose Aufbauend auf dem Erfolg von 2024, erwartet Redcare Pharmacy 2025 eine Margensteigerung und weiteres starkes Wachstum – inklusive einer Verdopplung des Rx-Umsatzes. 11.03.2025 / 06:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Aufbauend auf dem Erfolg von 2024, erwartet Redcare Pharmacy 2025 eine Margensteigerung und weiteres starkes Wachstum – inklusive einer Verdopplung des Rx-Umsatzes. Konzernumsatz wächst 2024 um 32% auf EUR 2,4 Mrd. (Q4: +27%), mit DAC...

 PRESS RELEASE

EQS-News: Building on a successful 2024, Redcare Pharmacy expects marg...

EQS-News: Redcare Pharmacy N.V. / Key word(s): Annual Results/Forecast Building on a successful 2024, Redcare Pharmacy expects margin uplift and unabated fast growth in 2025, including a doubling of Rx. 11.03.2025 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Building on a successful 2024, Redcare Pharmacy expects margin uplift and unabated fast growth in 2025, including a doubling of Rx. Total sales +32% to EUR 2.4 bn in FY 2024 (Q4, +27%), with DACH +33% (Q4, 27%) and International +26% (Q4, 29%). Non-Rx sales +21% to EUR 1.6 b...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch